111 related articles for article (PubMed ID: 26062755)
1. MDM2 beyond cancer: podoptosis, development, inflammation, and tissue regeneration.
Ebrahim M; Mulay SR; Anders HJ; Thomasova D
Histol Histopathol; 2015 Nov; 30(11):1271-82. PubMed ID: 26062755
[TBL] [Abstract][Full Text] [Related]
2. MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice.
Mulay SR; Thomasova D; Ryu M; Anders HJ
Kidney Int; 2012 Jun; 81(12):1199-211. PubMed ID: 22297670
[TBL] [Abstract][Full Text] [Related]
3. p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases.
Thomasova D; Mulay SR; Bruns H; Anders HJ
Neoplasia; 2012 Dec; 14(12):1097-101. PubMed ID: 23308042
[TBL] [Abstract][Full Text] [Related]
4. Murine Double Minute-2 Prevents p53-Overactivation-Related Cell Death (Podoptosis) of Podocytes.
Thomasova D; Bruns HA; Kretschmer V; Ebrahim M; Romoli S; Liapis H; Kotb AM; Endlich N; Anders HJ
J Am Soc Nephrol; 2015 Jul; 26(7):1513-23. PubMed ID: 25349197
[TBL] [Abstract][Full Text] [Related]
5. Podocyte loss involves MDM2-driven mitotic catastrophe.
Mulay SR; Thomasova D; Ryu M; Kulkarni OP; Migliorini A; Bruns H; Gröbmayr R; Lazzeri E; Lasagni L; Liapis H; Romagnani P; Anders HJ
J Pathol; 2013 Jul; 230(3):322-35. PubMed ID: 23749457
[TBL] [Abstract][Full Text] [Related]
6. Murine Double Minute-2 Inhibition Ameliorates Established Crescentic Glomerulonephritis.
Mulay SR; Romoli S; Desai J; Honarpisheh MM; Kumar SV; Anders HJ; Thomasova D
Am J Pathol; 2016 Jun; 186(6):1442-53. PubMed ID: 27102769
[TBL] [Abstract][Full Text] [Related]
7. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation.
Debelec-Butuner B; Alapinar C; Varisli L; Erbaykent-Tepedelen B; Hamid SM; Gonen-Korkmaz C; Korkmaz KS
Mol Carcinog; 2014 Feb; 53(2):85-97. PubMed ID: 22911881
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide downregulates the expression of p53 through activation of MDM2 and enhances activation of nuclear factor-kappa B.
Odkhuu E; Mendjargal A; Koide N; Naiki Y; Komatsu T; Yokochi T
Immunobiology; 2015 Jan; 220(1):136-41. PubMed ID: 25172547
[TBL] [Abstract][Full Text] [Related]
10. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
12. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
13. The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury.
Joshi Y; Sória MG; Quadrato G; Inak G; Zhou L; Hervera A; Rathore KI; Elnaggar M; Cucchiarini M; Marine JC; Puttagunta R; Di Giovanni S
Brain; 2015 Jul; 138(Pt 7):1843-62. PubMed ID: 25981963
[TBL] [Abstract][Full Text] [Related]
14. Murine double minute 2: p53-independent roads lead to genome instability or death.
Bouska A; Eischen CM
Trends Biochem Sci; 2009 Jun; 34(6):279-86. PubMed ID: 19447627
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
[TBL] [Abstract][Full Text] [Related]
16. Mdm2-mediated ubiquitylation: p53 and beyond.
Marine JC; Lozano G
Cell Death Differ; 2010 Jan; 17(1):93-102. PubMed ID: 19498444
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MDM2 attenuates neointimal hyperplasia via suppression of vascular proliferation and inflammation.
Hashimoto T; Ichiki T; Ikeda J; Narabayashi E; Matsuura H; Miyazaki R; Inanaga K; Takeda K; Sunagawa K
Cardiovasc Res; 2011 Sep; 91(4):711-9. PubMed ID: 21498419
[TBL] [Abstract][Full Text] [Related]
18. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
19. MDM2 and MDMX in cancer and development.
Marine JC
Curr Top Dev Biol; 2011; 94():45-75. PubMed ID: 21295684
[TBL] [Abstract][Full Text] [Related]
20. Resistance acquisition to MDM2 inhibitors.
Cinatl J; Speidel D; Hardcastle I; Michaelis M
Biochem Soc Trans; 2014 Aug; 42(4):752-7. PubMed ID: 25109953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
